<DOC>
	<DOC>NCT02261077</DOC>
	<brief_summary>Study to investigate pharmacokinetics, safety and tolerability of Buscopan® after single rising dose and after multiple rising doses</brief_summary>
	<brief_title>Pharmacokinetics, Safety and Tolerability of Rising Doses of Buscopan® in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Butylscopolammonium Bromide</mesh_term>
	<mesh_term>Scopolamine Hydrobromide</mesh_term>
	<criteria>1. Healthy males based upon a complete medical history, including the physical examination, vital signs (BP, PR), 12lead ECG, clinical laboratory tests. There is no finding deviating from normal and of clinical relevance. There is no evidence of a clinically relevant concomitant disease. 2. Age ≥21 and age ≤50 years 3. BMI ≥18.5 and BMI &lt;30 kg/m2 (Body Mass Index) 4. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation 1. Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance 2. Evidence of a clinically relevant concomitant disease 3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders 4. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders 5. History of relevant orthostatic hypotension, fainting spells or blackouts 6. Chronic or relevant acute infections 7. History of relevant allergy/hypersensitivity (including allergy to drug or its excipients) as judged clinically relevant by the investigator 8. Intake of drugs with a long halflife (&gt; 24 hours) within at least one month or less than 10 halflives of the respective drug prior to randomization 9. Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to enrolment in the study or during the study 10. Participation in another trial with an investigational drug within two months prior to randomization 11. Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day) 12. Inability to refrain from smoking on trial days as judged by the investigator 13. Alcohol abuse (more than 40 g/day for males) 14. Drug abuse 15. Blood donation (more than 100 mL within four weeks prior to administration or during the trial) 16. Excessive physical activities within one week prior to administration or during the trial 17. Any laboratory value outside the reference range that is of clinical relevance 18. Inability to comply with dietary regimen of trial site 19. Hypersensitivity to hyoscine butylbromide and/or related drugs of these classes 20. History of megacolon 21. History of prostatic hyperplasia 22. History of mechanical stenosis of the gastrointestinal (e.g. after surgery of the gastrointestinal tract) 23. History of narrowangle glaucoma 24. History of tachycardic arrhythmias 25. History of myasthenia gravis 26. Bladderneck obstruction</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>